Oteracil

Oteracil

SCHEMBL464773

O=C(O)c1nc(=O)[nH]c(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 1.00
TSHR P16473 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
PTPRB P23467 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SLC6A5 Q9Y345 1/20 0.38
POLB P06746 1/20 0.37
ALDH1A1 P00352 1/20 0.35
PIN1 Q13526 2/20 0.35
JAK2 O60674 1/20 0.34
THRB P10828 1/20 0.34
CGAS Q8N884 1/20 0.33
ALOX15 P16050 1/20 0.30
NFKB1 P19838 1/20 0.30
BLM P54132 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oteracil SCHEMBL4648864 0.98 LMNA (0.95) LMNATSHRKDM4ECYP3A4CYP2C9
Oteracil SCHEMBL29572271 0.98 LMNA (0.95) LMNATSHRKDM4ECYP3A4CYP2C9
SCHEMBL15769086 0.79 LMNA (0.65) LMNATSHRSLC6A5POLB
SCHEMBL3114000 0.75
Water SCHEMBL15331255 0.73 LMNA (0.58) LMNATSHRKDM4ECYP3A4CYP2C9
SCHEMBL11254727 0.73 LMNA (0.57) LMNATSHRKDM4ECYP3A4CYP2C9
SCHEMBL3085104 0.69 LMNA (0.52) LMNAKDM4ECYP3A4CYP2C9PTPRB
SCHEMBL14072016 0.62 LMNA (0.45) LMNATSHRKDM4ECYP3A4CYP2C9
SCHEMBL10752092 0.62 LMNA (0.44) LMNAKDM4ECYP3A4CYP2C9PTPRB
SCHEMBL22783664 0.62 JAK2 (0.61) LMNAKDM4EHSD17B10ALDH1A1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2131 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720132-A1 COMBINATION THERAPIES INVOLVING CLAUDIN 18.2 ANTAGONISTS FOR TREATMENT OF CANCER Suzhou Transcenta Therapeutics Co., Ltd. (CN) 2026-04-08 EP claimed
US-12595232-B2 DRG-MDM2-1 for use as a novel Mouse Double Minute 2 (MDM2) inhibitor BAHCESEHIR UNIVERSITESI (TR) 2026-04-07 US claimed
US-20260078184-A1 LAG-3 COMBINATION THERAPY FOR THE TREATMENT OF CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2026-03-19 US claimed
US-12576077-B2 Composition for preventing, alleviating or treating cancer CKP THERAPEUTICS, INC. (US) 2026-03-17 US claimed
EP-4667493-A2 LAG-3 COMBINATION THERAPY FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2025-12-24 EP claimed
US-12502392-B2 DRG-MDM2-6 for use as a novel mouse double minute 2 (MDM2) inhibitor BAHCESEHIR UNIVERSITESI (TR) 2025-12-23 US claimed
US-12435074-B2 Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor BAHCESEHIR UNIVERSITESI (TR) 2025-10-07 US claimed
EP-3957631-B1 QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2025-09-10 EP claimed
US-12398128-B2 Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor BAHCESEHIR UNIVERSITESI (TR) 2025-08-26 US claimed
EP-4602049-A1 SOS1 INHIBITORS Bayer Aktiengesellschaft (DE) 2025-08-20 EP claimed
US-5763280-A LYSING WITH A SURFACTANT; COMBINING WITH LIGAND TO FORM A STABLE CHROMOGEN WITH HEMOGLOBIN COULTER INTERNATIONAL CORP. (US) 1998-06-09 US claimed
US-5525603-A MIXTURE OF 2,4-DIHYDROXYPYRIDINE COMPOUND AND OXONIC ACIDADMINISTERED WITH TEGAFUR; SIDE-EFFECT REDUCTION TAIHO PHARMACEUTICAL CO., LTD. (JP) 1996-06-11 US claimed
EP-0443028-B1 NON-INJECTION CARCINOSTATIC AGENT FOR SUPPRESSING OCCURRENCE OF INFLAMMATION DUE TO 5-FLUOROURACIL AND METHOD FOR CURING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-09-29 EP claimed
EP-0543015-A1 COMPOSITION, METHOD AND KIT FOR POTENTIATING ANTITUMOR ACTIVITY AND FOR CURING TUMOR TAIHO PHARMACEUTICAL CO., LTD. (JP) 1993-05-26 EP claimed
US-5116600-A Oxonic acid OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-05-26 US claimed
EP-0445239-A4 ANTI-MALARIAL COMPOSITION AND METHOD OF USE 1992-03-25 EP claimed
EP-0445239-A1 ANTI-MALARIAL COMPOSITION AND METHOD OF USE THE CATHOLIC UNIVERSITY OF AMERICA (US) 1991-09-11 EP claimed
EP-0443028-A1 NON-INJECTION CARCINOSTATIC AGENT FOR SUPPRESSING OCCURRENCE OF INFLAMMATION DUE TO 5-FLUOROURACIL AND METHOD FOR CURING CANCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-08-28 EP claimed
WO-1991000081-A2 ANTI-MALARIAL COMPOSITION AND METHOD OF USE THE CATHOLIC UNIVERSITY OF AMERICA (US) 1991-01-10 WO claimed
US-4329381-A Method for providing corrosion resistance to metal objects HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 1982-05-11 US claimed